by Sheri Farsakh on 4/1/15
Discussing the invigorating field of regenerative medicine created quite the atmosphere last week when you consider the tremendous potential at hand for investors and patients. Key opinion leaders and life science investment experts and analysts shared their view on the topics at hand:
- Gene Therapy Delivery: What can be accomplished with existing vector technology & how should we expect it to evolve?
- Adoptive T-Cell Therapies: Considering key upcoming clinical & commercial milestones
The experience took a reviving turn as we spotted some of Integrium's very own clients pitching in front of the various biotech funding groups. The Alliance for Regenerative Medicine put on a great event alongside Piper Jaffray, their supporting bank, Maxim Group, and industry sponsors including CIRM and PCG Advisory Group.
